Back to News
Market Impact: 0.3
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Alector granted Genentech exclusive rights to develop and commercialize AL050, an investigational GCase enzyme replacement therapy delivered using Alector’s proprietary blood-brain barrier platform, Alector Brain Carrier (ABC). The announcement provides no financial terms or development milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ALEC0.65
More News
- Why is Alector stock surging today?
- Security researcher claims to they found KVM guest-host escape flaw
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status
- Schneider Electric drops $22.6B on PTC as datacenter boom rains money on infra companies
- Security researcher claims they found KVM guest-host escape flaw
- Brazil Election: Bolsonaro Pushes Lula to Brink as Markets Set to Rally